The endocannabinoid system in borderline personality disorder and antisocial personality disorder: A scoping review

doi: 10.1002/bsl.2576.

Online ahead of print.

Wilson Ho^1 2, Nathan J Kolla^{1 2 3 4 5}

Affiliations

PMID: 35575169
DOI: 10.1002/bsl.2576

Abstract

Individuals with borderline personality disorder (BPD) or antisocial personality disorder (ASPD) are overrepresented in forensic settings. Yet, despite the burden these disorders place on healthcare and criminal justice systems, there remains a lack of evidence-based pharmacological treatments. Epidemiological data have shown that comorbid cannabis use disorders are common in BPD and ASPD. ∆⁹ -Tetrahydrocannabinol, the primary psychoactive constituent of cannabis, is an exogenous cannabinoid that stimulates the endocannabinoid system (ECS). Hence, an investigation of the ECS in these conditions is warranted. This scoping review screened 105 records and summarized the extant research on the ECS in ASPD (n = 69) and BPD (n = 61) participants. Preliminary results suggest that alterations of the ECS may be present in these disorders. Although research examining the ECS in personality disorders is still in its infancy, more research is warranted given initial positive findings.

Keywords: anandamide; antisocial personality disorder; borderline personality disorder; endocannabinoid system; fatty acid amide hydrolase; genetics; neuroimaging.

References

REFERENCES

1. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596
1. Baczkowski, B. M., Van Zutphen, L., Siep, N., Jacob, G. A., Domes, G., Maier, S., Sprenger, A., Senft, A., Willenborg, B., Tüscher, O., Arntz, A., & Van de Ven, V. (2017). Deficient amygdala-prefrontal intrinsic connectivity after effortful emotion regulation in borderline personality disorder. European Archives of Psychiatry and Clinical Neuroscience, 267, 551-565. https://doi.org/10.1007/s00406-016-0760-z
1. Basavarajappa, B. S. (2007). Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Current Neuropharmacology, 5(2), 81-97. https://doi.org/10.2174/157015907780866910
1. Bechara, A., Dolan, S., Denburg, N., Hindes, A., Anderson, S. W., & Nathan, P. E. (2001). Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers. Neuropsychologia, 39(4), 376-389. https://doi.org/10.1016/s0028-3932(00)00136-6
1. Bedse, G., Bluett, R. J., Patrick, T. A., Romness, N. K., Gaulden, A. D., Kingsley, P. J., Plath, N., Marnett, L. J., & Patel, S. (2018). Therapeutic endocannabinoid augmentation for mood and anxiety disorders: Comparative profiling of FAAH, MAGL and dual inhibitors. Translational Psychiatry, 8(1), 92. https://doi.org/10.1038/s41398-018-0141-7